Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL

Inclusion Criteria

• •1. Relapsed or refractory B cell derived acute lymphoblastic leukemia(ALL), chronic lymphoblastic leukemia(CLL) and non-hodgkin lymphoma.
• •2. KPS\>60.
• •3. Life expectancy\>3 months.
• •4. Gender unlimited, age from 18 years to 70 years.
• •5. CD19 or CD20 expression must be detected on greater than 15% of the malignant cells by immunohistochemistry or greater than 30% by flow cytometry.
• •6. Patients who have failed at least one line of a standard treatment.
• •7. No serious mental disorder.
• •8. Patients must have adequate cardiac function(no cardiac disease, LVEF≥40% ), adequate pulmonary function as indicated by room air oxygen saturation of \>94%, and adequate renal function(Cr≤133umol/L).
• •9. No other serious diseases(autoimmune disease, immunodeficiency etc.).
• •10. No other tumors.
• •11. Patients volunteer to participate in the research.